Showing results (161-170 of 238) with videos related to
Sort By:
Pageof 24
Nature Medicine|February 5, 2013
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALLGannie Tzoneva, Arianne Perez-Garcia, Zachary Carpenter, et al.Leukemia Research|March 27, 2013
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129Dan Douer, Lynette N Zickl, Charles A Schiffer, et al.The Journal of Experimental Medicine|December 14, 2011
ETV6 mutations in early immature human T cell leukemiasPieter Van Vlierberghe, Alberto Ambesi-Impiombato, Arianne Perez-Garcia, et al.Blood|August 3, 2013
Genetic loss of SH2B3 in acute lymphoblastic leukemiaArianne Perez-Garcia, Alberto Ambesi-Impiombato, Michael Hadler, et al.Blood|November 27, 2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaAdele K Fielding, Jacob M Rowe, Georgina Buck, et al.Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.Blood|October 13, 2006
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyAdele K Fielding, Susan M Richards, Rajesh Chopra, et al.Blood|March 25, 2006
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trialMats Brune, Sylvie Castaigne, John Catalano, et al.Nature Medicine|February 28, 2012
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALLGiusy Della Gatta, Teresa Palomero, Arianne Perez-Garcia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocolMarc R Mansour, Maria L Sulis, Veronique Duke, et al.Pageof 24